* Virios Therapeutics Inc VIRI.OQ reported a quarterly
adjusted
loss of 5 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -8 cents. The mean expectation of
three analysts for the quarter was for a loss of 6 cents per
share. Wall Street expected results to range from -7 cents to -5
cents per share.
* Reported revenue was zero; analysts expected zero.
* Virios Therapeutics Inc's reported EPS for the quarter was
a
loss of 5 cents.
* The company reported a quarterly loss of $1.05 million.
* Virios Therapeutics Inc shares had fallen by 12.9% this
quarter and lost 67.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 58.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Virios
Therapeutics Inc is $1.00
This summary was machine generated from LSEG data August 8 at
03:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.06 -0.05 Beat
Mar. 31 2024 -0.04 -0.07 Missed
Dec. 31 2023 -0.09 -0.06 Beat
Sep. 30 2023 -0.09 -0.06 Beat